Malignant soft tissue sarcoma Cancer Sarcoma
Conditions
Interventions
Each center will be asked to prepare a list of eligible patients based on inclusion and exclusion criteria. If no database of soft tissue sarcoma (STS) patients is available, the institution data mana
Sponsors
Nanobiotix
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Primary Soft Tissue Sarcoma (STS) of the extremities and trunk wall newly pathologically diagnosed between 2008 and 2012 with STS. 2. Age = 18 years old 3. Any histology (except those specified in exclusion criteria below) 4. Any grade 5. Treated by any of these therapies for the primary tumor: 5.1. Surgery alone 5.2. Surgery + radiation therapy (pre, post or per-operative) 5.3. Surgery + chemotherapy (pre or post-operative) 5.4. Surgery + chemo-radiation (pre or post-operative) 5.5. ILP (isolated limb perfusion) and surgery +/- radiation therapy
Exclusion criteria
Exclusion criteria: 1. Patients with the following histological type: bone sarcoma, Kaposi's sarcoma, primitive neuroectodermal tumor, angiosarcoma, epithelioid hemangioendothelioma 2. Benign or intermediate histological subtypes: aggressive fibromatosis, desmoid tumor or dermatofibrosarcoma protuberans 3. Gastrointestinal stromal tumour (GIST) 4. STS localized in the intra-abdominal region and retroperitoneal region 5. Re-resection for non carcinological first resection (R1 or R2) 6. Patient with metastatic disease at diagnosis of STS 7. No pathological report available at diagnosis or at surgery 8. Less than 36 months (pilot and extended phase) of data available following diagnosis unless the patient died before 9. No possibility to have access to the data 10. Concurrent active therapy for another cancer (= patient receives active treatment for this cancer during the study period)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease free survival is measured through medical record review 3 years after disease diagnosis. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Pathological response (% of necrosis, % of fibrosis, % of viable cells) is measured through review of the pathological report of the surgical specimen at the time of surgery 2. Tumor type and subtype is assessed through pathological report review at diagnosis and the time of surgery 3. Chemotherapy treatment (drug name, drug dose, treatment duration, number of cycles) is assessed by reviewing drug prescription form at each course of chemotherapy and at the end of chemotherapy treatment 4. Radiation treatment (Dose delivered, treatment duration) is assessed by reviewing medical radiation report at the end of Radiation treatment 5. Surgical procedure (conservative surgery, amputation, R0 resection, R2 resection) is assessed by reviewing the medical surgery report at the time of surgery 6. Quality of surgery (R0 resection, R1 resection, surgical margin, tumor size) is measured by reviewing pathological reports at the date of surgery 7. New tumors (local recurrence, distant recurrence, other cancer) are assessed by reviewing medical report and radiological MRI and CT scan report on the date of surgery, 6 months after surgery, 12 months after surgery, 18 months after surgery, 24 months after surgery, 30 months after surgery, 36 months after surgery 8. Quality of life (Performans status, walking distance, presence at work) is measured by reviewing medical reports on the date of diagnosis of the tumor, date of surgery, 6 months after surgery, 12 months after surgery, 18 months after surgery, 24 months after surgery, 30 months after surgery, 36 months after surgery | — |
Countries
Belgium, Canada, France, Germany, Hungary, Italy, Poland, Spain, United Kingdom
Contacts
Public ContactEveline Boucher
Outcome results
None listed